一个自我激活和保护模块增强了全原抗CD70CAR-T细胞的临床前性能
Zhao Zhang1, Lianfeng Zhao1, Tinghui Huang1
1Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, China.
Frontiers in immunology
|February 5, 2025
概括
全球CAR-T (UCAR-T) 疗法显示出前景,但面临免疫排斥和耐用性问题. 一种新型的自我激活和保护 (SAP) 模块增强了UCAR-T细胞的生存和功能,克服了潜在的现成细胞疗法的这些局限性.
科学领域:
- 免疫治疗是一种免疫疗法.
- 细胞疗法细胞疗法
- 在瘤学瘤学.
背景情况:
- 全基化化学抗原受体T (CAR-T) 疗法或通用CAR-T (UCAR-T) 疗法在可访问性和成本方面具有优势.
- 临床UCAR-T应用受到免疫排斥,功效降低和耐久性有限的阻碍.
研究的目的:
- 开发和评估一个新的自我激活和保护 (SAP) 模块,集成到抗CD70UCAR-T细胞中.
- 克服免疫排斥并增强UCAR-T细胞的生存和功能.
主要方法:
- 选安全的抗CD70单链可变片段 (scFv) 来构建CAR-T细胞.
- 通过淘汰TRAC,B2M和HLA-DRA,生成了抗CD70的UCAR-T细胞.
- 将一个包含CD47和IL7Rα域的"全合一"SAP模块集成到CAR支架中.
主要成果:
- 萨普UCAR-T细胞显著减少了先天性免疫排斥,在体外和体内都提高了存活率和功能.
- 修改后的UCAR-T细胞表现出更好的持久性,没有观察到安全问题.
- 在规模化生产过程中,SAP UCAR-T 细胞保持了过程稳定性.
结论:
- 该SAP模块代表了前临床开发抗CD70UCAR-T.的前临床发展的有希望的战略.
- 这种方法为开发"现成"UCAR-T细胞治疗产品铺平了道路.
相关概念视频
T Cell Activation and Clonal Selection
638
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
638
Cell-mediated Immune Responses
66.7K
Overview
66.7K


